跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
AURO-RIVASTIGMINE
Authorized
STANDARD
AURO-RIVASTIGMINE
auro pharma inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a6b63556cb8115a7
Company
auro pharma inc
Type
Standard
Approval Details
Approval Id
a6b63556cb8115a7
Drug Approval Canada Name
AURO-RIVASTIGMINE
Product Name
AURO-RIVASTIGMINE
Status
Dormant
Status Date
2018-08-01
Original Market Date
2016-04-12
Din
02427567
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521001
Company Name
auro pharma inc
Company Address
3700 Steeles Avenue West, Suite 402, Woodbridge, Ontario, Canada, L4L 8K8
Active Ingredients
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
1.5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a6b63556cb8115a7
Type
Standard
Back to Health Canada Approvals
AURO-RIVASTIGMINE - Health Canada Drug Approval Details